Conclusions & Recommendations
16.1.8 - General Recommendations to ITI
Conclusion/Recommendation:
Improve visibility on surveys needed and conducted:
In each country tab, include table on impact and surveillance survey methodologies and funder.
As survey results come in, send key survey metrics to TEC liaison, along with results:
- Type of Survey (TT-only; TF 3% +/-2; etc)
- Number of EUs
- Population per EU
- Number of clusters
- Number of 1-9 year olds and 15+ per cluster
- Location of clusters within EU
- Funder
Action:
The table on survey methodologies and funders will be included alongside the
applications in the TEC18 book.
TEC 16
2017
surveys, TEC meeting management
16.10.1 - Democratic Republic of the Congo
Conclusion/Recommendation:
The TEC notes that ITI should not pay clearance fees and the MOH should explore working with WHO to facilitate the drug clearance process or issue a waiver for future shipments.
Action:
TEC recommendation was shared with the country. ITI is planning a country visit to address ongoing supply chain challenges for program year 2018.
TEC 16
2017
Africa - West,Africa - Central/Southern
DRC
supply chain, Zithromax® donation criteria
16.11.1 - Malawi
Conclusion/Recommendation:
The TEC notes that the last round of surveillance surveys is scheduled for 2020 and invites the MOH and partners to make a presentation at TEC 17 on an overview of F and E activities post-MDA.
Action:
TEC recommendation was shared with the MOH and the national program coordinator and partner have been invited to make a presentation at TEC 17.
TEC 16
2017
Africa - Central/Southern
Malawi
surveys, end game, F&E/WASH, TEC meeting management
16.12.1 - Mozambique
Conclusion/Recommendation:
The TEC recommends no new drug be shipped to Mozambique until the supply chain and program issues identified during the program assessment are corrected, documented, and verified. Both the 2017 and 2018 requests are placed in RS.
Action:
TEC recommendation was shared with the MOH and implementing partner. No drugs have been shipped in 2017. The national program worked with partners to address the recommendations made in the program assessment in April 2017.
TEC 16
2017
Africa - Central/Southern
Mozambique
supply chain, Zithromax® donation criteria
16.13.1 - Zimbabwe
Conclusion/Recommendation:
The TEC notes that baseline surveys are not yet complete and encourages the MOH to identify additional funding partners. ITI wish to support further implementation where needed through the provision of Zithromax®.
Action:
TEC recommendations were shared with the MOH. The national program has submitted a proposal to ESPEN for funding additional baseline surveys.
TEC 16
2017
Africa - Central/Southern
Zimbabwe
surveys, funding, suspected endemic
16.14.1 - Ethiopia
Conclusion/Recommendation:
The TEC recognizes with enthusiasm that Ethiopia has nearly reached full geographic scale and the domestic financing in SNNPR and Somali Regions.
Action:
Domestic financing from both Regional Health Bureaus was confirmed for 33 districts (29 in
SNNP and 4 in Somali regions) to support 2016 MDAs (conducted during the first half of
2017). Continuation funding for these 33 districts is pledged but subject to confirmation.
TEC 16
2017
Africa - East
Ethiopia
funding
16.14.2 - Ethiopia
Conclusion/Recommendation:
The TEC noted the Federal Ministry of Health’s plan to integrate preventive chemotherapy NTD activities in April and November each year. While supportive, the TEC and partners recognize that this may present challenges for aligning funding and implementing partners, and for ITI’s ability to send adequate Zithromax® to the country on time.
Action:
ITI informed the Federal Ministry of Health in early 2017 that providing adequate Zithromax®
in time for the November integrated MDA would not be possible this year. The FMOH moved
forward with their NTD integrated treatment plans, despite multiple logistic and financing
challenges raised by the partners. As anticipated Zithromax® was not available in the
quantities required to meet their deadline, and partners’ outstanding concerns are yet to be
resolved. ITI speaks regularly with their program coordinator to ensure he feels supported.
TEC 16
2017
Africa - East
Ethiopia
funding
16.14.3 - Ethiopia - SNNPR
Conclusion/Recommendation:
The TEC noted that surveillance surveys are due in 2018 in Gamo Gofa and encourages the Regional Health Bureau to identify a funding partner.
Action:
Impact surveys are currently underway and results are pending.
TEC 16
2017
Africa - East
Ethiopia
surveys, funding, end game
16.14.4 - Ethiopia - Gambella
Conclusion/Recommendation:
The TEC invites an application for the new Nguenyiel Camp if the FMOH would like to treat there, without need to conduct an additional survey given the origin of the refugees and the endemicity of trachoma in the region.
Action:
The RHB and FMOH requested Zithromax® to treat Nguenyiel Camp, which was approved.
MDA has already been conducted as part of 2017 interventions.
TEC 16
2017
Africa - East
Ethiopia
special populations, Zithromax® donation criteria, evaluation units
16.15.1 - Uganda
Conclusion/Recommendation:
The TEC noted the lack of evidence from the Western region of Uganda in districts bordering known endemic districts, and encourages the MOH to work with the WHO to develop a plan for assessing whether these warrant interventions. This will support the future successful development of the trachoma validation dossier.
Action:
The MOH, in partnership with RTI/ENVISION, are planning to map 15 of the 64 unmapped
districts in FY 2018 using the Tropical Data service.
TEC 16
2017
Africa - East
Uganda
end game, suspected endemic, evaluation units